Bioengineers from Georgia Institute of Technology, Atlanta, Georgia, US have invented a flow-diverter system that offers an effective treatment for aneurysm with active monitoring of intra-aneurysmal haemodynamics.
Three-dimensional (3D) printing shows promise in elucidating answers in the management of complex birth defects, assists in the planning of complex surgical procedures and facilitates stroke rehabilitation, but is beset with various challenges.
Computer and electrical engineers from The State University of New Jersey, US recently designed a cell counting platform that can be integrated with a wristband with readouts linkable to a mobile phone application.
The use of a wearable cardioverter-defibrillator (WCD) may be a suitable alternative for paediatric patients with life-threatening ventricular arrhythmias who are not candidates for implantable cardioverter-defibrillators (ICDs), a recent study showed.
A nasal device that reduces the ability to smell can lead to weight loss and changes in dietary preference for sweet stuff in adults younger than 50 years with obesity, suggesting a novel approach to managing obesity, according to a pilot study presented at the recent European Congress on Obesity (ECO) in Vienna, Austria.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Cardiology - Malaysia digital copy today!
Use of aspirin in the primary prevention of cardiovascular disease (CVD) in patients with no prior CVD history yields protection against the risks of acute myocardial infarction (AMI) and ischaemic stroke, but at the expense of an increase of similar magnitude in the incidence of major bleeding, according to the results of a recent meta-analysis presented at the European Society of Cardiology (ESC) Congress 2019 in Paris, France.
A comprehensive model of care delivered by nonphysician health workers (NPHWs), involving primary care physicians and families that was informed by local context, substantially improved blood pressure (BP) control and cardiovascular disease (CVD) risk, according to results of the HOPE 4 trial reported at the European Society of Cardiology (ESC) Congress 2019 and World Congress of Cardiology (WCC) 2019.